Amgen can market a biosimilar version of Stelara from January 2025 after J&J resolved its infringement lawsuit that centred on two Stelara patents.
A prior art reference does not qualify, says the Federal Circuit, dashing the firm’s hope to invalidate five catheter technology patents.
Lawyers from Axinn, Veltrop & Harkrider explore a case that could have major implications for generic drugs, biosimilars, and how skinny labels are read.
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.
The ‘formidable’ three bring 52 years’ experience from Fish & Richardson collectively | ‘Extensive’ patent trial background includes branded Hatch-Waxman litigation.